Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim Pharma Gmbh & Co Kg

Bi Pharma Kg.

Manfred Graulich

Rolf Banholzer

Helmut Meissner

Andreas Mathes

Peter Specht

Christian Kulinna

Peter Sieger

Michael Trunk

Sven Luettke

Wolfgang Broeder

Peter Seiger

Michael Josef Friedrich Trunk

Crystalline monohydrate of (1&#x3b1;,2&#x3b2;,4&#x3b2;,5&#x3b1;,7&#x3b2;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.

Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions

A method of making a physically stable and homogenous powdered pharmaceutical composition comprising a tiotropium salt and a physiologically acceptable excipient, the method comprising:

Powder formulations containing tiotropium suitable for inhalation

Crystalline monohydrate of (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-&lsqb;(hydroxydi-2-thienylacetyl)oxy&rsqb;-9,9-dimethyl-3-oxa-9-azoniatricyclo&lsqb;3.3.1.0 &rsqb;nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.

The invention relates to a new process for preparing a scopine ester useful as an intermediate in preparing (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-&lsqb;(hydroxydi-2-thienylacetyl)oxy&rsqb;-9,9-dimethyl-3-oxa-9-azoniatricyclo&lsqb;3.3.1.0 &rsqb; nonane-bromide.

Process for preparing a scopine ester intermediate

The invention relates to a new process for preparing (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-&lsqb;(hydroxydi-2-thienylacetyl)oxy&rsqb;-9,9-dimethyl-3-oxa-9-azoniatricyclo&lsqb;3.3.1.0 &rsqb; nonane-bromide.

Growing community of inventors

Waldalgesheim, Germany

Manfred Graulich